Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review by Maynard-Smith, Laura et al.
Maynard-Smith et al. BMC Infectious Diseases  (2014) 14:709 
DOI 10.1186/s12879-014-0709-7RESEARCH ARTICLE Open AccessDiagnostic accuracy of the Xpert MTB/RIF assay for
extrapulmonary and pulmonary tuberculosis when
testing non-respiratory samples: a systematic
review
Laura Maynard-Smith1, Natasha Larke2, Jurgens A Peters1 and Stephen D Lawn1,3*Abstract
Background: Although the evidence base regarding the use of the Xpert MTB/RIF assay for diagnosis of pulmonary
tuberculosis (TB) when testing respiratory samples is well established, the evidence base for its diagnostic accuracy
for extrapulmonary and sputum-scarce pulmonary TB when testing non-respiratory samples is less clearly defined.
Methods: A systematic literature search of 7 electronic databases (Medline, EMBASE, ISI Web of Science, BIOSIS,
Global Health Database, Scopus and Cochrane Database) was conducted to identify studies of the diagnostic
accuracy of the Xpert assay when testing non-respiratory samples compared with a culture-based reference standard.
Data were extracted and study quality was assessed using the QUADAS-2 tool. Sensitivities and specificities were
calculated on a per-sample basis, stratified by sample type and smear microscopy status and summarised using forest
plots. Pooled estimates were calculated for groups with sufficient data.
Results: Twenty-seven studies with a total of 6,026 non-respiratory samples were included. Among the 23 studies
comparing Xpert and culture done on the same samples, sensitivity was very heterogeneous with a median sensitivity
of 0.83 (IQR, 0.68–0.94) whereas specificities were typically very high (median, 0.98; IQR, 0.89–1.00). The pooled summary
estimates of sensitivity when testing smear-positive and smear-negative samples were 0.95 (95% CI 0.91–1.00)
and 0.69 (95% CI 0.60-0.80), respectively. Pooled summary estimates of sensitivity varied substantially between
sample types: lymph node tissue, 0.96 (95% CI, 0.72-0.99); tissue samples of all types, 0.88 (95% CI, 0.76–0.94);
pleural fluid, 0.34 (95% CI, 0.24–0.44); gastric aspirates for diagnosis of sputum-scarce pulmonary TB, 0.78 (IQR,
0.68 – 0.85). Median sensitivities when testing cerebrospinal fluid and non-pleural serous fluid samples were 0.85
(IQR, 0.75-1.00) and 0.67 (IQR, 0.00-1.00), respectively.
Conclusion: Xpert detects with high specificity the vast majority of EPTB cases with smear-positive non-respiratory
samples and approximately two-thirds of those with smear-negative samples. Xpert is a useful rule-in diagnostic
test for EPTB, especially when testing cerebrospinal fluid and tissue samples. In addition, it has a high sensitivity for
detecting pulmonary TB when using gastric aspirate samples. These findings support recent WHO guidelines regarding
the use of Xpert for TB diagnosis from non-respiratory samples.
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Extrapulmonary disease accounts for between 10% and
42% of cases of tuberculosis (TB), with the proportion
being greater among children and those with immu-
nodeficiency due to HIV co-infection [1,2]. Following
haematogenous spread of bacilli during primary pulmonary
infection, extrapulmonary TB (EPTB) may later develop
in any anatomic location [3]. Once the diagnosis has been
considered, confirmation can be difficult, with sample
collection from deep-seated tissues being challenging and
the disease typically being paucibacillary. Culture on solid
and/or liquid media is the gold standard for diagnosis.
However, prolonged turnaround times and limited labora-
tory infrastructure in resource-limited settings undermine
the utility of culture-based diagnosis in clinical practice.
Histology is widely used for diagnosis where the technical
expertise exists, but this is technically demanding, lacks
specificity and is time-consuming [4]. Existing nucleic acid
amplification tests (NAAT) used in high-resource settings
have some utility although, to date, have been overly
complex to use in most resource-limited settings.
The Xpert MTB/RIF (Xpert) assay (Cepheid Inc.,
Sunnyvale, CA, USA) is a cartridge-based, semi-automated,
rapid molecular assay, which permits rapid TB diagnosis
through detection of the DNA of Mycobacterium tubercu-
losis and simultaneous identification of a majority of the
mutations that confer rifampicin resistance (which is
highly predictive of multi-drug resistant TB [MDR-TB])
[5]. The evidence base regarding the use of Xpert on
sputum samples in the diagnosis of pulmonary TB (PTB)
in a wide range of high and low-burden settings is strong,
with pooled summary estimates of sensitivity when testing
smear positive and smear negative samples of 98% (95% CI,
97 – 99%) and 68% (95% CI, 59 – 75%), respectively, and a
pooled specificity of 98% (95% CI, 97 – 99%) [6]. The assay
has been CE-marked as compliant with European Union
legislation, approved by the United States Federal Drug
Administration (FDA) and was first endorsed by the World
Health Organization (WHO) in 2010 for use as the initial
diagnostic test in individuals suspected of having pulmon-
ary MDR-TB or HIV-associated pulmonary TB [7]. While
the assay is being widely implemented in many high burden
countries for this purpose, uncertainty remains concerning
its potential role in diagnosis of EPTB [8]. In addition, the
utility of testing non-respiratory samples for the diagnosis
of sputum-scarce PTB remains unclear, including gastric
aspirate or stool samples in children unable to produce
sputum.
An increasing number of studies have now examined
the diagnostic accuracy of Xpert for TB diagnosis when
testing a wide range of non-respiratory sample types and
using a culture-based reference standard. In light of the
need to develop/refine global and national guidelines on
the use of Xpert when testing non-respiratory samples,this systematic review evaluated and synthesized the
available data, taking into account the wide range of
different types of samples studied.
Methods
Search strategy
A systematic search of Medline, EMBASE, ISI Web of
Science, BIOSIS, Global Health Database, Scopus and
Cochrane Database of Systematic Reviews was carried
out on 6 November 2013 to identify journal articles and
conference abstracts reporting data on the diagnostic
accuracy of the Xpert MTB/RIF assay when testing non-
respiratory samples. There were no restrictions on study
design, patient demographics or whether TB case finding
was active or passive. Reference lists of included studies
and review articles were hand-searched. The study con-
formed to the PRISMA statement [9].
The search strategy is laid out in brief below:
(Free text search terms) “tubercul*” OR “TB” OR
“MDR-TB” OR “XDR-TB” OR (Subject heading term)
“Tuberculosis”
AND
(Free text search terms) “Xpert” OR “MTB/RIF Assay”
OR “MTB/RIF” OR “GeneXpert” OR “Cepheid”.
Citations were exported into Endnote X7 and duplicates
were removed. Two reviewers independently selected
titles and abstracts against inclusion and exclusion criteria
and the full text of any potentially relevant papers was
reviewed.
Eligibility criteria
Eligible studies reported on the diagnostic accuracy of
Xpert MTB/RIF for TB when testing non-respiratory
clinical samples (specifically excluding sputum, broncho-
alveolar lavage fluid, nasopharyngeal aspirates and tracheal
aspirates). Studies of both active and passive case finding
were included, but those in which samples were selected
based on pre-screening with another assay (eg smear
microscopy) were excluded. Data reporting on the testing
of gastric aspirate and stool samples for diagnosis of pul-
monary TB were also included, as were studies examining
the utility of testing urine samples to diagnose dissemi-
nated TB in HIV-infected patients. Acceptable reference
standards were culture of Mycobacterium tuberculosis
complex on solid and/or liquid media. Studies using
other reference standards were excluded. The reference
standard for rifampicin resistance was phenotypic drug
susceptibility testing (DST).
There were no limits on the number of participants in a
study or on the publication date. Studies were excluded if
they were not in the English language, if they referred only
to respiratory specimens, or if the results of respiratory
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not be disaggregated. When authors reported studies with
duplicated data, only the study with the larger sample size
was included.
Data extraction and data analysis
Data extraction, verification and study quality assessment
were conducted by two of the authors using a standardised
data extraction form. The retrieved data included country
of study, age-group, gender and HIV status of patients,
study setting, types and number of samples tested. The
numbers of true positives (tp), true negatives (tn), false pos-
itives (fp) and false negatives (fn) were extracted on a per
sample basis and entered into 2×2 tables. Sensitivity and
specificity were calculated from these tables as tp/(tp + fn)
and tn/(tn + fp), respectively, with 95% confidence intervals.
Since some papers presented data from multiple sample
types, multiple estimates were extracted from individual pa-
pers. No data were extracted on a per patient basis. In stud-
ies which used a composite reference standard, the culture
results alone were used as the reference standard.
The primary analyses comprised sensitivity and specifi-
city estimates calculated using all sample types from each
paper, but these were disaggregated into two groups
according to whether the culture-based reference testing
was done on the same sample as the Xpert test or on a
different sample. To investigate potential sources of
heterogeneity, estimates of sensitivity and specificity were
calculated separately for the following sample types: (i)
lymph node biopsies and fine needle aspirates; (ii) all
tissue types (including lymph node samples); (iii) cerebro-
spinal fluid (CSF); (iv) pleural fluid samples; and (v) non-
pleural serous fluid samples. Additionally estimates were
calculated separately for smear positive and smear nega-
tive samples and gastric aspirate samples as a method of
diagnosing pulmonary tuberculosis. Data were presented
on forest plots.
Median values and interquartile ranges (IQRs) for
sensitivity and specificity were calculated for the primary
analysis and all subanalyses. Pooled estimates of sensitivity
and specificity for the analyses by sample type and smear
status were calculated in Stata, using the bivariate random
effects and random effects models, respectively [10]. In
studies with small numbers of samples, zero events in cells
of the 2×2 table, often precluded calculation of pooled
estimates of sensitivity/specificity; and in these cases
median values and IQRs were calculated. Data on the
sensitivity and specificity of Xpert MTB/RIF for detection
of rifampicin resistance (compared to phenotypic drug
susceptibility) were also examined.
Quality assessment
Quality assessment of studies was performed using the
QUADAS-2 tool, examining bias and applicability of thestudies with respect to four separate domains: patient
selection, index test, reference standard and the flow
and timing of patients through the study [11]. No overall
summary score was calculated, but for each domain, any
concern with regards to bias and applicability were
qualified as ‘low’, ‘high’ or ‘unclear’. These results were
then presented in graph and table form.
Results
Studies included
Of a total of 1096 citations, there were 387 unique
potentially relevant citations identified and 301 of these
were excluded after evaluation of the title and abstract
(Figure 1). Of the remaining 86 papers selected for full
text review, 55 papers were subsequently excluded, and
31 papers containing data on the diagnostic accuracy of
Xpert MTB/RIF for TB when testing non-respiratory sam-
ples were reviewed in detail [12-38]. Of these, 27 studies
published between January 2009 and November 2013 were
eligible for inclusion in the qualitative and quantitative
synthesis and reported on a total of 6026 non-respiratory
samples (Table 1). Four additional studies were excluded
on the basis of either using a composite reference stand-
ard (n = 2) [39,40], including only samples known to be
smear-positive (n = 1) [41] or providing per patient instead
of per sample data (n = 1) [42] (Additional file 1: Table S1).
In the 27 studies included, the number of samples
studied ranged between 7 and 1,476, with a median of
115 (IQR, 39 – 340) (Table 1). Ten studies were from
Europe, eight from Africa, seven from Asia and one
from both North and Central America. The estimated
TB incidence rates in the countries where studies were
performed ranged between 3.6/100,000 population/year
(USA) to 1003/100,000 population/year (South Africa) in
2012 [1]. Most studies (20 of 27) were prospective, 6 were
retrospective and in one this was unclear. Twelve studies
tested samples of only one type, whereas the remaining fif-
teen studies reported on testing of multiple sample types.
The proportion of samples which were culture positive in
the studies ranged from 5 – 100% (Table 1).
Three studies enrolled only children, 5 included only
adults, 3 included all age-groups and the remaining 16
studies did not specify participant ages. Patient gender
was reported in only 11 studies, with males comprising
between 39.3% and 88.2% of participants. Among the 11
studies which reported HIV status, the proportions who
were positive ranged between 0% and 100%. Study set-
tings were classified as ‘clinical’ if patients were recruited
to the study (14 studies), and ‘laboratory’ if samples were
selected for inclusion within the laboratory (13 studies).
Methodological quality of included studies
The methodological quality of included studies was
assessed using the QUADAS-2 checklist [11]. A
31 papers 
underwent data 
extraction
55 papers excluded after full text review
• 19 purely abstracts with insufficient data
• 4 review articles
• 5 news articles
• 2 WHO guidelines
• 1 case study
• 10 studies using respiratory specimens only
• 2 studies where sample types are not specified as respiratory or non-
respiratory
• 2 studies combined results of respiratory and non-respiratory specimens
• 2 studies present no Xpert data
• 2 studies do not use culture as gold standard
• 1 study uses duplicate data
• 5 foreign language studies
86 papers selected 
for full text review
1010 papers excluded after first screen
• 709 duplicates
• 301 excluded on basis of title or abstract
Search 6th November 2013:
1096 potentially relevant citations 
identified from electronic databases
27 papers 
included in 
meta-analysis
4 papers excluded from review following data 
extraction:
• 2 only used composite reference standards
• 1 only included smear positive samples
• 1 included only per patient data for analysis
Figure 1 Selection of studies reporting on the use of the Xpert MTB/RIF assay for diagnosis of tuberculosis from non-respiratory
clinical samples.
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high risk of bias in the patient selection and flow and tim-
ing domains (41% and 15% respectively) (Additional file 2:
Figure S1 and Additional file 3: Figure S2). Within the
patient selection domain, studies were considered to be at
high risk of bias if a case–control study design was used,
or because the study excluded certain groups of patients.
The main reason studies were considered at high risk of
bias within the flow and timing domain, was because the
same reference standard was not used for all patients, or
because not all the samples included in the study had been
accounted for in the analysis. In 13 of 27 (48%) studies,
applicability was considered of high concern with regard
to patient selection in the laboratory-based studies.
Overall diagnostic accuracy of Xpert MTB/RIF
Among the 23 studies comparing Xpert MTB/RIF with
culture of the same sample or paired samples obtained
from the same anatomic location of disease, the median
sensitivity and specificity were 0.83 (IQR, 0.68 – 0.94;
range, 0.25 – 1.00) and 0.98 (IQR, 0.89 - 1.00; range,
0.73 – 1.00), respectively (Figure 2). In contrast, among
those studies (n = 4) in which the reference standardincluded culture of sample types which were different to
the non-respiratory sample tested with Xpert (for example,
sputum), the median sensitivity of Xpert was much lower
(0.22; range 0.19 – 0.48) [18,19,23,30,31].
Diagnostic accuracy in different sample types for EPTB
Disaggregated data were available by sample type for
lymph node biopsies and fine needle aspirates, all tissue
types (including lymph node samples), cerebrospinal
fluid (CSF), pleural fluid and non-pleural serous fluid
(pericardial, ascitic and synovial fluid).
The specificity of the Xpert assay was typically very
high when used to test samples of all types, with median
values of 1.00 for all sample types, including CSF, pleural
fluid, non-pleural serous fluid, all tissue samples, lymph
node sample and gastric aspirates. Pooled estimates of
specificity could not be calculated for CSF or non-
pleural serous fluids due to small numbers of samples in
these studies, but pooled summary estimates for the
remainder ranged from 0.93 to 0.99 (Table 2). The
pooled specificity for lymph node tissue (0.93, 95% CI
0.70 - 0.99) was less than that for all tissue samples com-
bined (0.98, 95% CI 0.87 – 0.99) (Table 2, Figure 3).
Table 1 Characteristics of included studies
First
author
Year Age (years) %
male
%
HIV
Study
setting
Sampling
method*
Gold
standard
Sample types (total
n specimens analysed)
Sample used for
gold standard
Composite reference
standard included
Studies included in meta-analysis
Ablanedo-
Terrazas
2013 Adults >16
(Median 29,
IQR 24–35.5)
88.2 100 Clinical Prospective Solid and/
or liquid culture
Lymph node FNA, lymph
node tissue biopsy (68)
As for Xpert N/A
Mexico Consecutive
Al-Ateah 2012 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Lymph node FNA, Pericardial,
Peritoneal/ascites fluid, Synovial/
articular fluid, Pus/abscess (67)
As for Xpert N/A
Saudi
Arabia
Consecutive
Armand 2009 NR NR NR Laboratory Retrospective Solid and/
or liquid
culture
Pleural fluid, Urine, Lymph node,
Bone marrow, Pus/abscess\
As for Xpert N/A
France Convenience
Bates 2011 Children <15,
(Median 20 months,
IQR 12 – 74 months)
NR 30.5 Clinical Prospective Liquid
culture
Gastric aspirate (788) As for Xpert N/A
Zambia Consecutive
Causse 2009 Mean 45,
Range 5 - 83
63.8 NR Clinical Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural
fluid, Gastric aspirate, Pericardial,
Peritoneal/ascitic, Synovial/
articular, Pus/abscess (340)
As for Xpert N/A
Spain Consecutive
Deggim 2010 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural
fluid, Peritoneal/ascitic (7)
As for Xpert N/A
Switzerland Consecutive
Feasey 2013 Adults only, 37 67 100 Clinical Prospective
Unspecified
Solid and/
or liquid
culture
Blood (104) Sputum and/or blood N/A
Malawi
Friedrich 2011 NR NR NR Clinical Prospective
Consecutive
Liquid
culture
Pleural fluid (25) Sputum and/or Abrams
needle biopsy and/or
pleural fluid
Culture and/or clinical
presentation plus ADA
level plus good response
to anti-TB treatment
South
Africa
Hanif 2009 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Pleural fluid, Urine,
Gastric aspirate, Pus,
Lymph node FNA (29)
As for Xpert N/A
Kuwait Unspecified
Hillemann 2011 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Urine, Gastric aspirate, Faeces (521)
As for Xpert N/A
Germany Consecutive
Ioannidis 2011 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Urine, Lymph node, Gastric
aspirate, Pericardial, Synovial/
articular, Pus/abscess (39)
As for Xpert N/A
Greece Unspecified
Lawn 2012 Adults >18 39.3 100 Clinical Retrospective Liquid
culture
Urine (168) Sputum N/A
South
Africa
Consecutive
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Table 1 Characteristics of included studies (Continued)
Ligthelm 2011 4.2% under 5; 12.5%
between 5 and 20;
83.3% over 20
41.6 18.8 Clinical Prospective Liquid
culture
Lymph node FNA (48) As for Xpert Cytomorphology suggestive
of TB with direct visualisation
of the organism and/or
bacterial culture
South
Africa
Unspecified
Malbruny 2011 Median 52 59.8 NR Laboratory Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Urine, Lymph node, Gastric aspirate,
Bone marrow, Peritoneal/ascitic fluid,
Synovial/articular, Pus/abscess (122)
As for Xpert N/A
France Unspecified
Miller 2011 NR NR NR Laboratory Retrospective Solid and/
or liquid
culture
NR (23) As for Xpert N/A
USA Unspecified
Moure 2011 NR NR NR Laboratory Retrospective Liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Gastric aspirate, Faeces, Lymph
node, Pericardial, Peritoneal/
ascitic fluid, Synovial/articular,
Pus/abscess (149)
As for Xpert N/A
Spain Unspecified
Nhu (a) 2013 Children under 16 NR NR Clinical Retrospective Liquid
culture
Gastric aspirate (49) As for Xpert Confirmed case (acid-fast bacilli
on smear microscopy or positive
culture) or probable case (clinical
symptoms consistent with TB, did
not receive an alternative diagnosis
and received TB treatment)
Vietnam Consecutive
Nhu (b) 2013 Adults >18 NR 20.8 Clinical Prospective Liquid
culture
CSF (379) As for Xpert Culture and/or clinical symptoms
and/or CSF criteria and/or cerebral
imaging and/or evidence TB
elsewhere
Vietnam Consecutive
Nicol 2013 Children <15
(Median 31 months,
IQR 19 – 57 months)
NR 14.8 Clinical Prospective Liquid
culture
Stool (115) Sputum N/A
South
Africa
Consecutive
Peter 2012 Median 35,
IQR 28-38
41 100 Clinical Prospective Liquid
culture
Urine (175) Sputum and/or non-
sputum
N/A
South
Africa
Random
Porcel 2013 Mean 50 58 0 Clinical Prospective Solid
culture
Pleural fluid (67) As for Xpert Smear and/or culture of pleural
fluid/sputum; or granuloma on
pleural biopsy; or lymphocytic
effusion with increased ADA;
and resolution of effusion
with TB treatment
Spain Consecutive
Teo 2011 NR NR NR Laboratory Unspecified Solid and/
or liquid
culture
CSF, Urine, Pleural fluid, Pericardial
fluid, Peritoneal/ascitic fluid, Tissue/
biopsy, Pus/abscess (31)
As for Xpert N/A
Singapore Unspecified
Tortoli 2012 NR NR NR Laboratory Retrospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Urine, Pleural
fluid, Gastric aspirate, Pus/abscess,
Peritoneal, Synovial/articular,
Pericardial (1493)
As for Xpert Culture and/or radiological and/or
histological signs suggesting TB
and improvement after anti-TB
treatment
Italy Consecutive
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Table 1 Characteristics of included studies (Continued)
Vadwai 2011 Median 37,
8 months – 94 years
45.9 3 Clinical Prospective Solid and/
or liquid
culture
CSF, Tissue/biopsy, Pleural fluid,
Lymph node FNA, Pericardial,
Peritoneal/ascitic fluid, Synovial/
articular, Pus/abscess (547)
As for Xpert Confirmed (culture) or probable
(clinical symptoms, radiological
findings and/or histology/cytology
suggestive of TB) or possible (only
clinical symptoms and/or signs
suggestive of TB)
India Consecutive
Van Rie 2013 Aged >18, Mean
25.8, Range 18 – 73
51 100 Clinical Prospective Liquid
culture
Lymph node FNA (373) As for Xpert Culture and/or smear
microscopy and/or cytology
South
Africa
Consecutive
Zeka 2011 Median 47.5 57.6 NR Clinical Prospective Solid and/
or liquid
culture
Pleural fluid, Tissue/biopsy,
Peritoneal/ascitic fluid, CSF,
Pericardial fluid, Urine (176)
As for Xpert Culture and/or clinical diagnosis
(clinical, pathological and/or
radiological findings)Turkey Unspecified
Zmak 2013 NR NR NR Laboratory Prospective Solid and/
or liquid
culture
Blood, CSF, Pleural fluid, Urine,
Faeces, Pericardial fluid,
Peritoneal/ascitic fluid,
Tissue/biopsy, Skin swabs (241)
As for Xpert N/A
Croatia Unspecified
*Sample selection: Study units selected prospectively, or retrospectively from existing samples; Consecutive, random or convenience sampling method. ‘Unspecified’ refers to studies where there was no clear
indication how the study participants were chosen.
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Figure 2 Sensitivity and specificity of Xpert MTB/RIF assay (A) against culture on same sample type; (B) against culture on different
sample types. (A) Median sensitivity 0.83 (IQR 0.68 – 0.94), median specificity 0.98 (IQR 0.89 – 1.00); (B) Median sensitivity 0.22 (range 0.19 – 0.48),
median specificity 0.99 (range 0.98 – 1.00)
Maynard-Smith et al. BMC Infectious Diseases  (2014) 14:709 Page 8 of 15In contrast to specificity, sensitivity for TB was very
heterogeneous within and between all sample types.
Median values for sensitivity ranged from 0.37 – 0.97.
The highest pooled estimate was for lymph node tissue
(0.96, 95% CI 0.72 – 0.99, n = 6), which was lower when all
tissue samples were aggregated (0.88, 95% CI 0.77 – 0.95,
n = 11). The lowest pooled sensitivity estimate was that for
testing pleural fluid samples (0.34, 95% CI 0.24 – 0.44,
n = 9) (Figure 3, Table 2).Table 2 Sub-analyses of sensitivity and specificity by sample
Sample Statistical model
for pooled estimates
Number
of studies
Sensitivity
Pooled estimate
(95% CI)
CSF Cannot calculate 10
Pleural fluid Bivariate 9 0.34 (0.24 – 0.44)
Non-pleural
serous fluid
Cannot calculate 4
All tissue Bivariate 12 0.88 (0.77 – 0.95)
Lymph node
biopsy/FNA
Bivariate 7 0.96 (0.72 – 0.99)
Gastric aspirate Bivariate 8 0.78 (0.69 – 0.86)
Smear positive Random effects 9 0.95 (0.91 – 1.00)
Smear negative Random effects 10 0.69 (0.60 – 0.80)Diagnostic accuracy in gastric aspirate and stool samples
for PTB
As shown with other sample types, the specificity of using
Xpert to test gastric aspirates for diagnosis of pulmonary
TB is extremely high (pooled estimate 0.99, 95% CI 0.98 –
0.99, range, 0.98 – 1.00), with a sensitivity pooled estimate
of 0.78 (95% CI 0.69 – 0.86, range, 0.67 – 1.00) (Figure 4).
Three studies reported on Xpert testing of stool samples
compared to culture, but sample sizes were small at 2, 3,type and smear status
Specificity
Median (IQR) Pooled estimate
(95% CI)
Median (IQR)
0.85 (0.75 – 1.00) 1.00 (0.98 – 1.00)
0.37 (0.27 – 0.72) 0.98 (0.96 – 0.99) 1.00 (0.98 – 1.00)
0.67 (Range 0.00 – 1.00) 1.00 (Range 1.00 – 1.00)
0.90 (0.73 – 0.99) 0.98 (0.87 – 0.99) 1.00 (0.89 – 1.00)
0.97 (0.71 – 1.00) 0.93 (0.70 – 0.99) 1.00 (0.94 – 1.00)
0.85 (0.74 – 1.00) 0.99 (0.98 – 0.99) 1.00 (0.99 – 1.00)
1.00 (0.98 – 1.00)
0.69 (0.61 – 0.83)
Figure 3 Sensitivity and specificity of Xpert MTB/RIF assay in different sample types (A - E).
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Hillemann et al. and Moure et al. papers were both 1.00,
and the specificity in the Hillemann et al. and Zmak et al.
papers were 0.92 and 1.00 respectively (data not shown on
forest plot).Figure 4 Sensitivity and specificity of Xpert MTB/RIF assay against a cTwo of the gastric aspirate studies were carried out
only with children: Bates et al., sensitivity 0.69 (95% CI
0.54 - 0.81), specificity 0.99 [95% CI 0.98 - 1.00]; Nhu
et al., sensitivity 0.82 (95% CI 0.48 - 0.98), specificity 1.00
(95% CI 0.90 – 1.00) [15,29]. One further study comparedulture reference standard on gastric aspirate samples.
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a sensitivity of 0.24 (95% CI 0.07 – 0.5) [30]. These results
could not be pooled due to the different reference stan-
dards between the gastric aspirate studies and the latter
study on stool samples. It is likely that the gastric aspirate
samples in other studies were collected from children, but
age-stratified data were not available and therefore could
not be included on an analysis of Xpert MTB/RIF in
children.
Association between diagnostic accuracy and smear
status and HIV status
Sub-analysis of studies comparing Xpert and culture on
smear positive and negative samples was conducted. The
sensitivity when testing smear-positive samples (pooled
estimate 0.95, 95% CI 0.91 – 1.00, range 0.92 – 1.00)
far exceeded that observed when testing smear-negative
samples (pooled estimate 0.69, 95% CI 0.60 – 0.80,
range 0.38 – 0.92) (Figure 5, Table 2). Only one study
provided specificity data for smear positive samples, so
pooled estimates and comparisons between smear posi-
tive and negative samples were not made.
It was not possible to adequately assess the relationship
between HIV status and diagnostic accuracy of Xpert
MTB/RIF as only 2 studies provided suitable data. Bates
et al. studied gastric aspirates from children and found that
sensitivity did not differ significantly between HIV negative
children (0.74, 95% CI 0.55-0.88) and HIV positive children
(0.63, 95% CI 0.36-0.84) [15]. In contrast, Nicol et al. tested
stool samples from children and found that the sensitivity
in HIV positive children (0.80, 95% CI 0.38-0.96) was
substantially higher than that observed in HIV negative
children (0.33, 95% CI 0.14-0.61; p-value 0.08) [30].
Variations in study methodology
Study methodology varied greatly across all 27 studies.
Sixteen studies used a combination of solid and/or liquid
culture as a reference standard, ten studies used only
liquid culture and one study used only solid culture
(Table 1). Sub-analyses of the pooled estimates for differ-
ent sample types and smear status by solid or liquid
culture were not possible, due to the large number of
studies using either solid, or liquid culture, or both.
The methods of studies using CSF and pleural fluid
samples were examined to try and establish differences
in accuracy when using concentrated and unconcen-
trated samples. Frequently the methods were not de-
scribed in sufficient detail (i.e. the volume of fluid used)
to allow for sub-analyses on this basis (Additional file 4:
Table S2).
Detection of rifampicin resistance
The accuracy of Xpert MTB/RIF for detecting rifampicin
resistance compared to phenotypic drug susceptibilitytesting (DST) was reported for non-respiratory samples
in only 6 studies. The total number of samples testing
positive for M. tuberculosis by Xpert MTB/RIF that were
tested by phenotypic DST was 259 and included a variety
of sample types (Table 3). However, the prevalence of
rifampicin resistance by phenotypic DST in these studies
was 0% for those carried out in Europe and sensitivity
could not be estimated [21,27,38]. The sensitivity for ri-
fampicin resistance was high in the remaining 3 studies
from Saudi Arabia (1.00), India (0.98) and South Africa
(1.00). Specificity was variable (range, 0.87-1.00).
Indeterminate test results and non-tuberculous
mycobacteria
The proportion of Xpert MTB/RIF indeterminate results
was reported by 14 studies, and the median was 1.4%
(IQR, 0–4.1%; range 0–26.9%). A high proportion (26.9%)
was reported by Feasey et al. when testing blood samples.
Three studies reported data on non-tuberculous mycobac-
teria (NTM) identified by culture from 79 samples. Of
these, 77 tested negative by Xpert and two had indeter-
minate results.
Discussion
In this systematic review, we have carefully evaluated the
literature on the diagnostic accuracy of the Xpert MTB/
RIF assay when used to test non-respiratory samples and
this synthesis supports its use in the diagnosis of both
EPTB and sputum-scarce pulmonary TB. The specificity
was very high across the majority of studies, highlighting
its utility as a rule-in test for TB diagnosis that can be
used to reliably inform the start of TB treatment when
positive. In contrast, sensitivity was extremely heteroge-
neous, with much higher sensitivity being typically seen
when testing lymph node samples, other tissue samples
and cerebrospinal fluid as compared to the results of test-
ing pleural fluid and other serous fluids. These findings
strongly support the recently released WHO recommen-
dations for the use of Xpert MTB/RIF for TB diagnosis by
testing CSF and tissue samples [43].
Sensitivity ranged between 0.25 and 1.00 when Xpert and
culture were both applied to the index non-respiratory
samples. A key source of heterogeneity was the smear-
status of samples as previously observed described when
testing sputum samples for pulmonary TB diagnosis [6].
Xpert reliably detected the vast majority of non-respiratory
samples testing smear-positive, culture-positive for M.
tuberculosis but approximately only two-thirds of smear-
negative samples. The type of non-respiratory sample tested
was another key variable associated with the heterogeneity
in sensitivity. Not only were pooled and median sensitivities
typically far higher when testing lymph node or other
tissue samples and cerebrospinal fluid compared to those
observed when testing pleural or other non-pleural serous
(A)
(B)
Figure 5 Sensitivity of Xpert MTB/RIF assay in (A) smear positive and (B) smear negative samples.
Table 3 Rifampicin resistance detection by Xpert compared to phenotypic drug susceptibility testing
Study Xpert positive
samples tested for
drug resistance (n)
Rifampicin resistance detection Prevalence of rif
resistance by DST
Sensitivity Specificity
TP FP FN TN
Al-Ateah 17 2 0 0 15 11.7% 1.00 1.00
Hillemann 26 0 1 0 25 0% Not estimable 0.96
Moure 63 0 0 0 63 0% Not estimable 1.00
Vadwai 125 39 5 1 80 31.2% 0.98 0.94
Zmak 12 0 0 0 12 0% Not estimable 1.00
Lawn* 16 1 2 0 13 6.3% 1.00 0.87
*Comparison of urine Xpert MTB/RIF vs sputum phenotypic DST.
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gastric aspirate samples highlighting an exciting new
opportunity in the diagnosis of sputum-scarce pulmonary
TB, which is potentially particularly useful in children.
Other potential sources of heterogeneity in sensitivity
include small sample sizes, differences in study design,
patient selection, patient age (adult versus child) and sam-
ple processing methodology. Despite this, high specificity
suggests that the Xpert assay could play a useful role as a
rapid rule-in test for diagnosis of EPTB, particularly when
used to test lymph node samples, tissue biopsies or CSF
samples. Limited sensitivity would, however, preclude use
of the assay to rule-out EPTB, especially when samples
have also been demonstrated to be smear-negative. Col-
lectively, these data suggest that this assay represents an
important advance in the diagnosis of EPTB and sputum-
scarce pulmonary TB using non-respiratory samples.
However, further well-designed, large studies are still
needed to definitively characterise the accuracy and
impact of this assay, optimum means of obtaining and
processing samples.
A systematic review recently published by Denkinger
et al., also carefully examined the use of the Xpert assay in
extrapulmonary TB [44]. They searched four databases
and included 18 papers with a total of 4461 samples,
compared to the 6026 samples from 27 studies included
in this review. The review by Denkinger et al. included
studies with more than 10 samples of either lymph
node tissue, cerebrospinal fluid or pleural fluid, and did
not examine the use of non-respiratory samples for diag-
nosing sputum-scarce pulmonary TB. They examined
sensitivity and specificity against both culture and com-
posite reference standards, and for each sample type found
that sensitivity increased and specificity decreased against
a composite reference standard. We did not compare the
findings of Xpert with a composite reference standard
since it was evident that this was a further source of sub-
stantial heterogeneity since composite reference standards
varied so much between studies.
The high pooled estimate of sensitivity we found in
smear positive samples (0.96, 95% CI 0.91 – 1.00) is
reflected in the findings by Denkinger et al. (0.97, 95%
CI 0.96 – 0.99). The latter did not analyse smear negative
samples, which our study found to have a much lower
pooled sensitivity estimate (0.69, 95% CI 0.60 – 0.80). The
very strong association between sample smear status and
the sensitivity of Xpert MTB/RIF is entirely consistent
with the findings observed when testing sputum samples,
reflecting the mycobacterial load present [6]. In vitro
experiments in which sputum samples have been spiked
with M. tuberculosis have found that the assay retains
95% reliability for detection of the organism in sputum
samples spiked with as few as 131 colony forming units
per millilitre [45]. Comparable data are not known fornon-respiratory samples types but the threshold for
detection may differ according to the degree of poly-
merase chain reaction (PCR) inhibition associated with
various sample types. The Xpert assay will provide an
invaluable aid to diagnosis of EPTB in which smears are
negative, especially in settings with otherwise limited
laboratory capacity. Moreover, for smear-positive samples,
Xpert provides a rapid and reliable means of differentiat-
ing between Mycobacterium tuberculosis complex and
non-tuberculous mycobacteria as well as providing a rapid
screening for rifampicin-resistance mutations.
We found a higher pooled sensitivity when testing lymph
node samples than Denkinger et al. who included data from
a larger number of studies (0.96, 95% CI 0.72 – 0.99, n = 7
compared with 0.83, 95% CI 0.71 – 0.91, n = 13) [44]. Sev-
eral of the studies that we included in the tissue sample
group did not describe from which anatomical location
the biopsies originated. It is likely that many of the add-
itional data included in that group are also lymph node
samples. This may explain why the pooled estimate for
all tissue samples in our study is more comparable with
the Denkinger et al. findings for lymph node tissue
(0.88, 95% CI 0.77 – 0.95, n = 12) [44]. Two studies
included in our review from South Africa used samples
obtained from lymph nodes via fine needle aspiration
and reported high sensitivities of 0.93 (Ligthelm et al.)
[24] and 0.97 (van Rie et al.) [36], with most of these
patients having HIV-coinfection. The very high sensi-
tivities reported are likely to reflect extremely high
mycobacterial burden within lymph nodes of these
patients and, consistent with this, van Rie et al. found
that sensitivity was inversely related to blood CD4 cell
counts. Ablanedo-Terrazas et al. tested both fine needle
aspirates and excision biopsies in HIV positive patients,
and found sensitivities of 1.00 regardless of the level of
immunosuppression [12]. Denkinger et al. examined
whether there was a difference in sensitivity between
studies with >10% HIV positive patients and <10%, and
found that accuracy rates did not differ [44]. This disparity
demonstrates that more work needs to be done to differ-
entiate the impact of HIV on the accuracy of Xpert in
tissue samples. As well as HIV-infected patients, children
may also benefit from improved diagnosis on lymph node
tissue, as up to 50% with extra-thoracic TB have been
shown to have cervical lymphadenitis [46].
TB meningitis (TBM) accounts for approximately 1%
of TB disease, but carries a very high mortality risk of
between 20% and 50% [47]. Prognosis worsens with later
presentation, which may be exacerbated by prolonged
time to diagnosis and treatment initiation. The sensitivity of
smear microscopy in some cases can be as low as 20% of
culture-confirmed disease, increasing with larger volumes
and longer examination times of CSF [48]. Although cul-
ture provides considerably increased sensitivity, prolonged
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TBM is frequently empirical. The high median sensitiv-
ity of Xpert when testing CSF (0.85, IQR 0.75 – 1.00) is
therefore an important finding, complemented by similar
findings by Denkinger et al. (pooled sensitivity 0.81, 95%
CI 0.59 – 0.92) [44]. One study by Patel et al, was
excluded from our data synthesis on the basis of its use of
a composite reference standard rather than culture alone
[39]. However, a key observation was that testing the
pellet from 3 ml of centrifuged CSF provided a sensitivity
of 0.65 (95% CI 0.47-0.80) compared to a sensitivity of
0.26 (95% CI 0.17 – 0.37; p <0.001) when just 1 ml of
uncentrifuged CSF was tested. Denkinger et al. compared
concentrated and unconcentrated samples in CSF samples
from several studies and also found that sensitivity and
specificity were higher in the former group (84.2% vs
51.3%, 98% vs 94.6% respectively) [44]. The study proto-
cols for all the studies included in this review have been
summarised, but there were not sufficient data available to
allow for further sub-analyses (Additional file 4: Table S2).
The lower sensitivities in pleural and non-pleural serous
fluid likely reflect the low bacillary burden in these sam-
ples. It is known that analysis of pleural biopsies rather
than pleural fluid increases microbiological diagnosis as
well as allowing histological evaluation [49]. The study by
Christopher et al., which was excluded on the basis of use
of composite reference standards, compared the Xpert
assay on both pleural fluid and pleural biopsies [40]. How-
ever, this study found no benefit from testing pleural bi-
opsy samples with Xpert. It was frequently unclear from
the studies of pleural disease in this review what volumes
of pleural fluid were used. As a result of this, sub-analyses
on the effect of centrifugation were not carried out as the
study methodologies for comparison could not be clearly
defined (Additional file 4: Table S2). Studies in the
Denkinger et al. review were found to have higher sensi-
tivities where the proportion of HIV patients was <10%,
and where a concentration step was used, but the paper
comments that the confidence intervals are wide and
overlapping. Further studies need to define optimum sam-
ple volumes for all sterile fluids, processing methodologies
and the yield from pleural biopsies.
Missed and delayed diagnosis of TB in children is com-
mon, due to non-specific presentation, paucibacillary
disease and the difficulty of expectorating sputum [50].
Two studies specifically sought to test gastric aspirates in
children suspected of PTB [15,29], where several other
studies incorporated gastric aspirates into a wider study
on all sample types with a mixed population. It is likely
that the samples from the latter group were also predom-
inantly children. The pooled sensitivity of Xpert on gastric
aspirate samples was 0.78 (95% CI 0.68 – 0.85) compared
to 0.25 for smear microscopy in the study by Bates
et al. [15]. Stool samples are another means of testingfor pulmonary disease in children, but the sample num-
bers in the studies included in this review comparing
Xpert to culture on stool are very small. Nicol et al. com-
pared stool samples to culture of sputum and found a sen-
sitivity of 0.24 (95% CI 0.07 – 0.5) [30]. The paucity of
age-stratified data in the studies in this review precluded
any specific analysis on the use of Xpert MTB/RIF assay
in children compared to adults.
Two further studies assessed the utility of Xpert in
detecting disseminated disease from urine in HIV-infected
out-patients and in-patients, using sputum culture as the
reference standard [23,31]. The sensitivity observed
among selected sick medical hospital in-patients (0.48;
95% CI 0.38 – 0.57) [31] was substantially higher than
that observed among unselected ambulatory out-patients
undergoing active screening regardless of symptoms prior
to starting antiretroviral therapy (0.19; 95% CI 0.11 – 0.29)
[23]. There was a strong inverse association between Xpert
sensitivity and blood CD4 cell count; sensitivity increased
to 0.60 in in-patients with CD4 count <100 cells/ml [31].
Frequently, such patients are sputum-scarce, preventing the
use of sputum smear microscopy, and therefore a rapid test
with this sensitivity is critical to those patients who may
have high mortality risk while waiting for culture results.
Moreover, in combination with another urine rapid test
(Determine TB-LAM), a more recent study has shown
that sensitivity in this group can be increased further to
0.85 (95% CI 0.75-0.92) [51]. These results demonstrate
that urine-based diagnosis may be particularly useful
for routine investigation among HIV-infected medical
in-patients.
A paucity of data precludes adequate evaluation of the
accuracy of the Xpert assay for detecting rifampicin
resistance from non-respiratory samples. The limited
data available are similar to those observed when testing
sputum samples with high sensitivity but sub-optimal
specificity in some studies. However, it should be noted
that all these studies were conducted prior to the launch
of the modified G4 version of the assay cartridges for
which evidence thus far shows much improved specifi-
city in sputum [52].
Particular strengths of this review include the analysis
of non-respiratory samples for diagnosis of PTB, the
comprehensive search strategy and comparison of data
to a uniform rigorous reference standard. Only five of
the original 387 potentially relevant citations from the
search needed to be excluded on the basis of language,
which is not expected to have significantly altered the
result. Stratification of data by sample type revealed the
comparative utility of the assay for different forms of
EPTB, and complements the meta-analysis by Denkinger
et al. [44]. The findings of the review are limited by dif-
ferences between studies including study design, clinical
populations and patient selection, small sample sizes and
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may have contributed to the marked degree of heterogen-
eity observed in the estimates of assay sensitivity. Insuffi-
cient data were available to adequately examine certain key
variables such as age (adults vs children) and HIV status.
An important unresolved issue regarding the use of
Xpert assay to test non-respiratory samples is the differing
processing requirements for each sample type. Technical
studies on optimum processing methods would enable the
highest rates in sensitivity to be achieved, as well as lower-
ing indeterminate rates. Adding in processing steps will
mean that use of the assay will likely be restricted to
secondary and tertiary care settings potentially limiting
the impact of this technology. Larger scale implementa-
tion and cost-effectiveness studies should be carried out
to identify the true benefits over culture in the time to
treatment initiation and subsequent benefits in clinical
outcomes. Further studies which allow stratification of
data by HIV status or level of immunosuppression may
inform how the assay might best be used in active case
finding, particularly in areas with high rates of HIV, either
alone or in combination with other diagnostic modalities.
Conclusions
The findings of this review confirm that the Xpert MTB/
RIF assay is an important advance in the diagnosis of
EPTB and support the WHO guidelines issued by WHO
in 2014 [43]. Principally, Xpert MTB/RIF is likely to be
of greatest utility when testing CSF and lymph node or tis-
sue samples, and differentiating tuberculous from non-
tuberculous mycobacteria in smear positive samples of any
type. In addition, there is clearly a role for testing gastric as-
pirate samples in diagnosis of sputum-scarce PTB. Further
studies are needed to expand the evidence base for use of
this assay for diagnosis of EPTB and PTB with different
forms of non-respiratory samples in a wide range of clinical
populations. However, the present data provide support for
current implementation of this assay for EPTB diagnosis.
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